Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AE Sphingosine-1-phosphate (S1P) receptor modulators
L04AE03 Siponimod
D11072 Siponimod fumarate (USAN) <JP/US>
USP drug classification [BR:br08302]
Central Nervous System Agents
Multiple Sclerosis Agents
Siponimod
D11072 Siponimod fumarate (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D11072 Siponimod fumarate (USAN); Siponimod fumaric acid (JAN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG03018 Siponimod
D11072 Siponimod fumarate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG03018 Siponimod
D11072 Siponimod fumarate
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Sphingolipid
S1PR1
D11072 Siponimod fumarate (USAN) <JP/US>
S1PR5
D11072 Siponimod fumarate (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11072
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11072
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11072
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11072
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11072
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG03018 Siponimod
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG03018 Siponimod